OA11287A - Method of enhancing bioavailability of fexofenadine and its derivatives. - Google Patents

Method of enhancing bioavailability of fexofenadine and its derivatives. Download PDF

Info

Publication number
OA11287A
OA11287A OA1200000032A OA1200000032A OA11287A OA 11287 A OA11287 A OA 11287A OA 1200000032 A OA1200000032 A OA 1200000032A OA 1200000032 A OA1200000032 A OA 1200000032A OA 11287 A OA11287 A OA 11287A
Authority
OA
OAPI
Prior art keywords
peg
glycoprotein
glycoprotein inhibitor
water soluble
inhibitor
Prior art date
Application number
OA1200000032A
Other languages
English (en)
Inventor
Dennis H Giesing
Kin-Kai Hwang
Gail H Hurst
Original Assignee
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel Inc
Publication of OA11287A publication Critical patent/OA11287A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/745—Polymers of hydrocarbons
    • A61K31/75—Polymers of hydrocarbons of ethene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
OA1200000032A 1997-08-14 2000-02-09 Method of enhancing bioavailability of fexofenadine and its derivatives. OA11287A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91156397A 1997-08-14 1997-08-14

Publications (1)

Publication Number Publication Date
OA11287A true OA11287A (en) 2003-10-22

Family

ID=25430473

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200000032A OA11287A (en) 1997-08-14 2000-02-09 Method of enhancing bioavailability of fexofenadine and its derivatives.

Country Status (30)

Country Link
EP (1) EP1003528B1 (pl)
JP (1) JP4295913B2 (pl)
KR (1) KR100522985B1 (pl)
CN (1) CN1143680C (pl)
AR (1) AR018505A1 (pl)
AT (1) ATE224721T1 (pl)
AU (1) AU725965C (pl)
BR (1) BR9811937A (pl)
CA (1) CA2301267C (pl)
CZ (1) CZ293666B6 (pl)
DE (1) DE69808303T2 (pl)
DK (1) DK1003528T3 (pl)
EE (1) EE04263B1 (pl)
ES (1) ES2179523T3 (pl)
HK (1) HK1025901A1 (pl)
HU (1) HU226823B1 (pl)
ID (1) ID24463A (pl)
IL (1) IL134521A (pl)
NO (1) NO325148B1 (pl)
NZ (1) NZ502133A (pl)
OA (1) OA11287A (pl)
PL (1) PL191607B1 (pl)
PT (1) PT1003528E (pl)
RU (1) RU2197967C2 (pl)
SK (1) SK283868B6 (pl)
TR (1) TR200000419T2 (pl)
TW (1) TWI240633B (pl)
UA (1) UA64765C2 (pl)
WO (1) WO1999008690A1 (pl)
ZA (1) ZA987221B (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0812195B1 (en) * 1995-02-28 2002-10-30 Aventis Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol compounds
KR100514264B1 (ko) * 1997-08-26 2005-09-15 아벤티스 파마슈티칼스 인크. 피페리디노알칸올-충혈완화제 조합용 제약 조성물
GB9822170D0 (en) * 1998-10-13 1998-12-02 Danbioyst Uk Ltd Novel formulations of fexofenadine
BR0306329A (pt) * 2002-05-29 2005-04-26 Aventis Pharmaceuticals Holdin Método de tratamento de asma
JP2008120684A (ja) * 2005-03-07 2008-05-29 Kumamoto Univ 抗アレルギー薬
KR101106374B1 (ko) 2009-06-05 2012-01-19 민병욱 고체연료에 의한 가연성 가스 발생 장치
KR101117014B1 (ko) * 2009-09-09 2012-06-14 민병욱 부패성 폐기물의 바이오매스 처리에 의한 폐자원 재활용 방법 및 장치
CN101843616B (zh) * 2010-06-04 2011-07-27 西安万隆制药有限责任公司 一种盐酸非索非那定与微晶纤维素组合物及其制备方法
RU2453315C2 (ru) * 2010-08-17 2012-06-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения аллергических заболеваний
CA2835912A1 (en) 2011-05-20 2012-11-29 Aventis Pharmaceuticals Inc. Pharmaceutical composition comprising fexofenadine
RU2504018C1 (ru) * 2012-05-28 2014-01-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Рязанский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения и социального развития Российской Федерации Способ моделирования состояния индукции функциональной активности гликопротеина-р финастеридом в эксперименте
RU2553362C1 (ru) * 2014-01-09 2015-06-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Рязанский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Способ моделирования состояния ингибирования функциональной активности гликопротеина-р линестренолом в эксперименте
CN104188998A (zh) * 2014-09-18 2014-12-10 中山大学 一种柚皮苷与盐酸非索非那丁药物组合物及其制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US5916566A (en) * 1995-06-07 1999-06-29 Avmax, Inc. Use of benzoin gum to inhibit P-glycoprotein-mediated resistance of pharmaceutical compounds
AU5893796A (en) * 1995-06-07 1996-12-30 Novo Nordisk A/S Modification of polypeptides

Also Published As

Publication number Publication date
PL191607B1 (pl) 2006-06-30
NO20000706L (no) 2000-04-13
CA2301267A1 (en) 1999-02-25
CN1143680C (zh) 2004-03-31
EP1003528A1 (en) 2000-05-31
KR20010022845A (ko) 2001-03-26
RU2197967C2 (ru) 2003-02-10
EP1003528B1 (en) 2002-09-25
IL134521A0 (en) 2001-04-30
HUP0003189A3 (en) 2001-04-28
HU226823B1 (hu) 2009-11-30
SK1842000A3 (en) 2000-08-14
NZ502133A (en) 2002-03-28
IL134521A (en) 2005-07-25
SK283868B6 (sk) 2004-03-02
JP4295913B2 (ja) 2009-07-15
CZ293666B6 (cs) 2004-06-16
HK1025901A1 (en) 2000-12-01
EE200000069A (et) 2000-10-16
HUP0003189A2 (en) 2001-03-28
DK1003528T3 (da) 2003-02-03
TWI240633B (en) 2005-10-01
ATE224721T1 (de) 2002-10-15
NO325148B1 (no) 2008-02-11
CA2301267C (en) 2004-07-13
ZA987221B (en) 1999-02-15
CN1267221A (zh) 2000-09-20
EE04263B1 (et) 2004-04-15
WO1999008690A1 (en) 1999-02-25
AU8505098A (en) 1999-03-08
UA64765C2 (uk) 2004-03-15
AR018505A1 (es) 2001-11-28
AU725965C (en) 2004-04-22
AU725965B2 (en) 2000-10-26
DE69808303T2 (de) 2003-05-22
NO20000706D0 (no) 2000-02-11
DE69808303D1 (de) 2002-10-31
BR9811937A (pt) 2000-09-05
ES2179523T3 (es) 2003-01-16
JP2001515041A (ja) 2001-09-18
PT1003528E (pt) 2003-02-28
ID24463A (id) 2000-07-20
TR200000419T2 (tr) 2000-09-21
KR100522985B1 (ko) 2005-10-21
PL338579A1 (en) 2000-11-06
CZ2000522A3 (cs) 2000-09-13

Similar Documents

Publication Publication Date Title
US6451815B1 (en) Method of enhancing bioavailability of fexofenadine and its derivatives
US7157424B2 (en) Pharmaceutical compositions for hepatitis C viral protease inhibitors
EP1474172B1 (en) Pharmaceutical compositions for hepatitis c viral protease inhibitors
AU725965B2 (en) Method of enhancing bioavailability of fexofenadine and its derivatives
ZA200307684B (en) Antifungal composition with enhanced bioavailability
CZ295090B6 (cs) Nová kombinace loteprednolu a antihistaminik
WO2008148515A1 (en) Intranasal administration of asenapine and pharmaceutical compositions therefor
US20230404918A1 (en) Fulvestrant formulations and methods of their use
US20050277584A1 (en) Pharmaceutical compositions comprising cyclosporins
RU2157687C2 (ru) Фармацевтические составы для парентерального введения, содержащие n-{4-[2-(1,2,3,4-тетрагидро-6,7-диметокси-2-изохинолинил)-этил]-фенил]-9,1 0-дигидро-5-метокси-9-оксо-4-акридинкарбоксамид
RU2266736C2 (ru) Способ и композиции для ингибирования артериосклероза
MXPA00001515A (en) Method of enhancing bioavailability of fexofenadine and its derivatives
US20060140985A1 (en) Lansoprazole formulations and related processes and methods
KR20220124891A (ko) 나파모스타트 또는 이의 염을 포함하는 에멀젼을 포함하는 약제학적 제제 및 이의 제조 방법
JP2004250442A (ja) エンドセリン血中濃度低下剤
WO2012010942A2 (en) Novel pharmaceutical composition(s) of hiv protease inhibitor(s)